COMMUNIQUÉS West-GlobeNewswire

Onconetix Highlights Realbotix AI Humanoid Robot Delivery Update
02/04/2026
Realbotix Announces Expected Delivery of 19 Robots in March, April, and May 2026 as it Scales Production Capacity; Onconetix recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a subsidiary of [...]
Intelligent Bio Solutions Completes Clinical Cut-off Study, Advances FDA 510(k) Clinical Program Targeting Multi-Billion-Dollar U.S. Drug Screening Market
02/04/2026
Study results finalized on schedule support FDA clearance and planned U.S. commercial launch Company advances second phase of clinical program for 510(k) submission with method comparison, usability, and interference [...]
MDIC appoints Philips Chief Medical Officer Carla Goulart Peron as new board member
02/04/2026
April 2, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that Carla Goulart Peron, MD, Chief Medical Officer at Philips, has been appointed [...]
Ultragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)
02/04/2026
If approved, UX111 will be the first approved therapy for the treatment of Sanfilippo syndrome Type A, a rare disease affecting young children that leads to progressive, irreversible neurodegeneration and early death [...]
MIMEDX to Sponsor Leading Advanced Wound Care Conferences
02/04/2026
Multispecialty Focus with Industry Leadership Aimed at Improving Patient Outcomes Company Will Feature Recent Additions to Its Advanced Wound Care Portfolio MARIETTA, Ga., April 02, 2026 (GLOBE NEWSWIRE) -- MiMedx Group [...]
Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium
02/04/2026
HOUSTON, April 02, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting [...]
Cartesian Therapeutics Announces New Employment Inducement Grants
02/04/2026
FREDERICK, Md., April 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today [...]
Emergent BioSolutions Participates in Upcoming International Preparedness Conferences
02/04/2026
GAITHERSBURG, Md., April 02, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS), a global life sciences leader with biodefense and medical countermeasures products, announced today that members of its [...]
Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections
02/04/2026
MALVERN, Pa., April 02, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for [...]
Curanex Expands Its Drug Development Pipeline to Include Cancer Cachexia, Representing a Multi-Billion-Dollar Market Opportunity and Important Step In The Company’s Evolution Into a Broader Therapeutics Development Company
02/04/2026
Company expands strategic focus into one of oncology’s most urgent supportive-care challenges Jericho, New York, April 02, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX) (“Curanex” or the “Company [...]
Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer
02/04/2026
Fast Track Designation highlights potential of CTIM-76 to address unmet need for patients with PROC CTIM-76 Phase 1a trial ongoing, with interim data expected in June 2026 PHILADELPHIA, April 02, 2026 (GLOBE NEWSWIRE [...]
Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive
02/04/2026
FDA Fast Track designation supports accelerated development and expedites regulatory review Norovirus is responsible for an estimated 685 million global cases each year and approximately $60 billion in worldwide [...]
From Lab Fiber to Luxury Fabric: Kraig Biocraft Laboratories Targets Apparel First with Engineered Spider Silk
02/04/2026
DENVER, April 02, 2026 (GLOBE NEWSWIRE) -- ( www.247marketnews.com ) -- Kraig Biocraft Laboratories (OTCQB: KBLB) is advancing a transgenic silkworm platform designed to produce recombinant spider silk at commercial [...]
Catalyst MedTech Announces Acquisition of X3D
02/04/2026
Expands OEM Platform and Strengthens Leadership in Nuclear Medicine Imaging PITTSBURGH, April 02, 2026 (GLOBE NEWSWIRE) -- Catalyst MedTech, a national leader in nuclear medicine and molecular imaging solutions, today [...]
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/04/2026
MONTREAL and CHARLOTTE, N.C., April 02, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a [...]
MyGevity Announces Nationwide Launch of Integrated Health Data Platform
02/04/2026
New system centralizes at-home DNA testing, biological age assessment, and lab diagnostics into a unified reporting experience ST. PETERSBURG, FL, April 02, 2026 (GLOBE NEWSWIRE) -- MyGevity announced the nationwide [...]
Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
02/04/2026
Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA-approved therapies [...]
Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
02/04/2026
Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findings Patients in the TED studies demonstrated greater levels of [...]
Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)
02/04/2026
Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA-approved therapies [...]

Pages